Comment on the editorial by Turner et al. on assessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk assessment vs. risk aversion by Zannad et al
Eur Heart J Cardiovasc Pharmacother
.
2017 Jul 1;3(3):129.
doi: 10.1093/ehjcvp/pvx006.
Authors
Kristina Dunder
1
,
Pieter A de Graeff
2
,
Eberhard Blind
3
Affiliations
1
Medical Products Agency (Läkemedelsverket), Dag Hammarskjölds väg 42, 75237 Uppsala, Sweden.
2
Dutch Medicines Evaluation Board, Utrecht, the Netherlands.
3
European Medicines Agency, London.
PMID:
28444250
DOI:
10.1093/ehjcvp/pvx006
No abstract available
Publication types
Letter
Comment
MeSH terms
Cardiovascular Diseases*
Cardiovascular System
Humans
Risk Assessment*
Risk Factors